Development of a dry distillation technology for the production of 131I using medium flux reactor for radiopharmaceutical applications
Rajwardhan Ambade(Bhabha Atomic Research Centre), Ashutosh Dash(Bhabha Atomic Research Centre), Mohammed Sahiralam Khan(Bhabha Atomic Research Centre), M. R. A. Pillai, P. V. Joshi(Bhabha Atomic Research Centre), Swamirao Namdeo Shinde(Bhabha Atomic Research Centre), Sharad P. Lohar(Bhabha Atomic Research Centre), K.V. Vimalnath(Bhabha Atomic Research Centre), Sudipta Chakraborty
Cited by 16
Related Papers
Production of 177Lu for Targeted Radionuclide Therapy: Available Options
|Nuclear Medicine and Molecular Imaging|2015|375
Sustained Availability of <sup>99m</sup>Tc: Possible Paths Forward
|Journal of Nuclear Medicine|2012|140
Peptide Receptor Radionuclide Therapy: An Overview
|Cancer Biotherapy and Radiopharmaceuticals|2015|122
Targeted Radionuclide Therapy - An Overview
|Current Radiopharmaceuticals|2013|117
Development of an electrochemical 90Sr–90Y generator for separation of 90Y suitable for targeted therapy
|Nuclear Medicine and Biology|2008|99